Several other brokerages have also commented on KIDS. BTIG Research reaffirmed a buy rating and set a $44.00 price target on shares of Orthopediatrics in a research report on Friday, May 10th. ValuEngine lowered shares of Orthopediatrics from a buy rating to a hold rating in a research report on Thursday, August 1st. Needham & Company LLC began coverage on shares of Orthopediatrics in a research report on Wednesday, June 19th. They set a buy rating and a $53.00 price target for the company. Finally, Zacks Investment Research lowered shares of Orthopediatrics from a buy rating to a hold rating in a research report on Tuesday, August 13th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Orthopediatrics has a consensus rating of Buy and an average price target of $44.25.
Shares of KIDS opened at $32.43 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 6.01 and a current ratio of 2.53. The company has a market capitalization of $463.73 million, a price-to-earnings ratio of -33.78 and a beta of 0.12. The company’s 50 day simple moving average is $34.53 and its 200 day simple moving average is $38.74. Orthopediatrics has a 1 year low of $25.11 and a 1 year high of $47.82.
A number of hedge funds have recently modified their holdings of the stock. US Bancorp DE increased its position in Orthopediatrics by 9.5% during the second quarter. US Bancorp DE now owns 4,307 shares of the company’s stock worth $168,000 after purchasing an additional 375 shares during the last quarter. Conestoga Capital Advisors LLC increased its position in Orthopediatrics by 4.4% during the second quarter. Conestoga Capital Advisors LLC now owns 10,395 shares of the company’s stock worth $405,000 after purchasing an additional 440 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Orthopediatrics by 1.4% in the second quarter. JPMorgan Chase & Co. now owns 34,418 shares of the company’s stock worth $1,326,000 after acquiring an additional 465 shares in the last quarter. Rhumbline Advisers increased its position in shares of Orthopediatrics by 6.6% in the first quarter. Rhumbline Advisers now owns 9,350 shares of the company’s stock worth $414,000 after acquiring an additional 580 shares in the last quarter. Finally, First Light Asset Management LLC increased its position in shares of Orthopediatrics by 0.5% in the second quarter. First Light Asset Management LLC now owns 123,260 shares of the company’s stock worth $4,807,000 after acquiring an additional 611 shares in the last quarter. 50.52% of the stock is owned by hedge funds and other institutional investors.
Orthopediatrics Company Profile
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Further Reading: What is a put option?
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.